Recombinant PDCD1 (Spartalizumab Biosimilar) 抗体
Quick Overview for Recombinant PDCD1 (Spartalizumab Biosimilar) 抗体 (ABIN7200669)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            原理
- Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody
- 
                                            特异性
- The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
- 
                                            产品特性
- Recombinant Humanized IgG4 Monoclonal Antibody.
- 
                                            纯化方法
- Protein A affinity column
- 
                                            纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 
                                            过滤
- 0.2 μm filtered
- 
                                            内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 
                                            免疫原
- The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.
- 
                                            亚型
- IgG4 kappa
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- 1 mg/mL
- 
                                            缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 
                                            储存液
- Without preservative
- 
                                            注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 
                                            储存条件
- -20 °C
- 
                                            储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - PDCD1 (Spartalizumab Biosimilar)
- 
                                            物质类
- Biosimilar
- 
                                            背景
- Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.
 抗原
- 
                    
 
                                     
                                     
                                    